Skip to main content
    P

    ProQR Therapeutics BV (PRQR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.47
    -0.01 (-0.68%)

    Market Cap: $208.86M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(26/39)
    Avg Surprise
    -14.99%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.11
    Range$-0.12 - $-0.10
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.14+22.3%
    60d ago$-0.14+21.2%
    30d ago$-0.14+21.2%
    7d ago$-0.110.0%
    Current$-0.11
    Revenue Consensus
    $5M
    Range$3M - $6M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.01
    Range$-0.08 - $0.09
    2 analysts
    Revenue Consensus
    $4M
    Range$-4456920 - $8M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.01---
    Sep 26EST
    		-$-0.11---
    Jun 26
    Reported Aug 13
    		$-0.10$-0.14+28.57%Beat+28.6%
    Mar 26
    Reported May 12
    		$-0.15$-0.18+16.67%Beat-36.4%
    Dec 25
    Reported Mar 12
    		$-0.09$-0.09-4.63%Miss-2.9%
    Sep 25
    Reported Nov 6
    		$-0.12$-0.17+29.41%Beat-50.0%
    Jun 25
    Reported Aug 7
    		$-0.14$-0.08-75.00%Miss-250.0%
    Mar 25
    Reported May 8
    		$-0.11$-0.16+31.25%Beat-10.0%
    Dec 24
    Reported Mar 13
    		$-0.09$-0.09+4.86%Beat-28.6%
    Sep 24
    Reported Nov 7
    		$-0.08$-0.14+42.86%Beat+0.0%
    Jun 24
    Reported Aug 8
    		$-0.04N/A+76.47%Beat+63.6%
    Mar 24
    Reported May 9
    		$-0.10$-0.16+37.50%Beat+23.1%
    Dec 23
    Reported Mar 13
    		$-0.07$0.01-800.00%Miss+56.3%
    Sep 23
    Reported Nov 7
    		$-0.08$-0.13+38.46%Beat+72.4%
    Jun 23
    Reported Aug 3
    		$-0.11$-0.12+8.33%Beat+52.2%
    Mar 23
    Reported May 16
    		$-0.13$-0.10-30.00%Miss+35.0%
    Dec 22
    Reported Mar 29
    		$-0.16$-0.16+0.00%Beat+42.9%
    Sep 22
    Reported Nov 9
    		$-0.29$-0.23-26.09%Miss-20.8%
    Jun 22
    Reported Aug 4
    		$-0.23$-0.22-4.55%Miss+17.9%
    Mar 22
    Reported May 5
    		$-0.20$-0.24+16.67%Beat+33.3%
    Dec 21
    Reported Feb 24
    		$-0.28$-0.12-133.33%Miss-7.7%
    Sep 21
    Reported Nov 4
    		$-0.24$-0.24+0.00%Beat+22.6%
    Jun 21
    Reported Aug 5
    		$-0.28$-0.27-3.70%Miss-211.1%
    Mar 21
    Reported May 6
    		$-0.30$-0.30+0.00%Beat+14.3%
    Dec 20
    Reported Feb 25
    		$-0.26$-0.25-4.00%Miss+33.3%
    Sep 20
    Reported Nov 16
    		$-0.31$-0.39+20.51%Beat+8.8%
    Jun 20
    Reported Aug 6
    		$-0.09N/A+74.29%Beat+73.5%
    Mar 20
    Reported May 7
    		$-0.35$-0.36+2.78%Beat+12.5%
    Dec 19
    Reported Feb 26
    		$-0.39$-0.35-11.43%Miss-2.6%
    Sep 19
    Reported Nov 6
    		$-0.34$-0.38+10.53%Beat-61.9%
    Jun 19
    Reported Aug 7
    		$-0.34$-0.43+20.93%Beat-25.9%
    Mar 19
    Reported May 8
    		$-0.40$-0.38-5.26%Miss+0.0%
    Dec 18
    Reported Feb 27
    		$-0.38$-0.26-46.15%Miss+17.4%
    Sep 18
    Reported Nov 7
    		$-0.21$-0.31+32.26%Beat+57.1%
    Jun 18
    Reported Aug 8
    		$-0.27$-0.47+42.55%Beat+50.9%
    Mar 18
    Reported May 9
    		$-0.40$-0.40+0.00%Beat+20.0%
    Dec 17
    Reported Feb 28
    		$-0.46$-0.48+4.17%Beat-15.0%
    Sep 17
    Reported Nov 20
    		$-0.49$-0.50+2.00%Beat-
    Jun 17
    Reported Aug 16
    		$-0.55$-0.51-7.84%Miss-
    Mar 17
    Reported May 17
    		$-0.50$-0.51+1.96%Beat-
    Dec 16
    Reported Feb 28
    		$-0.40$-0.53+24.53%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.74EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-228.20%Operating Margin-100.70%
    ROE-57.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.49xQuick Ratio3.49x
    Trading Statistics
    Beta0.20Avg Volume777.43K
    52-Week High$3.1052-Week Low$1.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.60
    SMA 20$1.67
    SMA 50$1.90
    SMA 200$1.73
    EMA 10$1.59
    EMA 20$1.67
    EMA 50$1.78
    EMA 200$1.80

    MACD

    Line: -0.10Signal: -0.10Hist: -0.01

    ADX

    ADX: 33.8+DI: 12.9-DI: 30.3

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$1.69

    Bollinger Bands

    Upper Band$1.91
    Lower Band$1.44
    %B Position2803%(Upper)
    Band Width0.06

    RSI (14-Day)

    Oversold
    27.8

    Momentum Oscillators

    Stoch %K12.2
    Stoch %D15.5
    Williams %R-86.2
    ROC (10d)-11.4%
    Momentum-0.19
    CCI (20d)-159.3
    MFI (14d)39.7

    Volatility Measures

    ATR (14d)$0.10(6.6%)
    StdDev (20d)0.12
    Hist Vol55.7%(High)

    Volume Flow

    VWAP$1.47
    OBV1.6M
    AD Line-8.7M
    CMF (20d)-0.139

    Volume Metrics

    Avg Vol (20d)782.0K
    Vol Ratio1.4x
    VWMA (20d)$1.64

    Pivot Points

    R3$1.71
    R2$1.67
    R1$1.57
    Pivot Point$1.53
    S1$1.43
    S2$1.39
    S3$1.29

    Advanced Oscillators

    TSI-35.33
    Ultimate Osc41.2
    KST-191.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.90M$2.07M$4.64M$2.92M$3.82M$4.52M$4.31M$3.84M$6.30M$4.45M$3.28M$1.37M
    Cost of Revenue$718,705$705,412$672,631N/AN/AN/AN/AN/A$714,596$695,067N/AN/A
    Gross Profit$8.19M$1.36M$3.97M$2.92M$3.82M$4.52M$4.31M$3.84M$6.30M$4.45M$3.28M$1.37M
    Operating Expenses$17.15M$15.23M$13.01M$14.20M$16.07M$15.34M$14.39M$12.56M$9.90M$12.53M$9.55M$8.76M
    R&D$12.88M$12.02M$9.83M$11.08M$11.41M$12.32M$10.61M$9.41M$7.05M$9.28M$7.73M$5.45M
    SG&A$4.91M$3.85M$3.89M$3.12M$4.82M$3.23M$3.91M$3.28M$3.01M$3.45M$4.75M$3.31M
    Operating IncomeN/A$-13,873,452$-9,039,430$-11,284,000$-12,249,000$-10,816,000$-10,081,000$-8,716,000$-3,600,000$-8,075,000$-6,268,000$-7,391,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$2,594$2,872$276,708$10,558
    Income Before Tax$-8,847,095$-13,603,078$-8,835,362$-11,006,000$-12,161,000$-10,079,000$-9,305,000$-8,108,000$-2,892,000$-7,655,000$-5,478,000$-5,379,001
    Income Tax Expense$25,413$1,000$0$0$18,000$0$0$0$-200,000$3,000$5,000$40,999
    Net Income$-8,872,510$-13,603,078N/A$-11,006,000$-12,179,000$-10,079,000$-9,305,000$-8,108,000$-2,692,000$-7,658,000$-5,483,000$-5,710,000
    EBITDAN/A$-12,909,078$-8,366,798$-10,335,000$-11,486,000$-9,401,000$-5,821,000$-8,166,000$-2,178,406$-6,961,128$-291,000$-4,726,443
    EBITN/A$-13,603,078$-9,039,429$-11,006,000$-12,161,000$-10,079,000$-6,492,000$-8,854,000$-2,889,406$-7,652,128$-1,019,000$-5,368,443
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRQR

    News

    FY2028 Earnings Estimate for PRQR Issued By HC Wainwright

    HC Wainwright has revised its FY2028 earnings per share estimate for ProQR Therapeutics (NASDAQ:PRQR) to a loss of $0.37, a reduction from its prior forecast of a $0.27 loss...

    MarketBeat•10/5/26•Somewhat-Bullish

    Press Releases about ProQR Therapeutics N.V. - Ordinary Shares (Nasdaq:PRQR)

    This article compiles various press releases from ProQR Therapeutics N.V. (Nasdaq: PRQR) covering a range of corporate and clinical updates. Key announcements include leadership appointments...

    FinancialContent•10/3/26•Somewhat-Bullish

    ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Stock Price, News, Quote & History

    ProQR Therapeutics N.V. (PRQR) is a biotechnology company focused on developing RNA-based therapies for genetic disorders. The article provides current stock information, including a last price of $1.6350...

    FinancialContent•10/2/26•Somewhat-Bullish

    ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

    ProQR Therapeutics announced the first human validation of its RNA-editing platform for liver disease, showing dose-dependent target engagement for its AX-0810 candidate. The treatment...

    Yahoo Finance•10/2/26•Bullish

    ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-09-30

    ProQR Therapeutics N.V. (PRQR) released a slide deck for a shareholder/analyst call held on September 30, 2026. The article highlights that the content was published in conjunction with this event and was prepared by...

    Seeking Alpha•10/1/26•Neutral

    PRQR Valuation and Fair Value

    P/E
    -2.7x
    PEG
    0.0x
    P/B
    1.8x
    See GNG's fair value

    PRQR Profitability: Margins, ROIC and FCF

    Gross margin
    88.7%
    Operating margin
    -100.7%
    Net margin
    -228.2%
    ROE
    -57.4%
    FCF margin
    -230.9%

    PRQR Competitors

    CompanyTicker
    Alector IncALEC
    Cartesian Therapeutics Inc.RNAC
    Protalix Biotherapeutics IncPLX
    Pro-Dex IncPDEX
    Owens & Minor IncOMI
    Exagen IncXGN
    Larimar Therapeutics IncLRMR
    Cybin IncCYBN

    Sector: Healthcare

    PRQR Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    1
    Buy
    8
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PRQR Bull Case vs Bear Case

    Bull case

    • PRQR beat EPS estimates in 75.0% of its last 8 reported quarters.
    • PRQR grew quarterly revenue 120.4% year over year.
    • 100.0% of PRQR's analyst ratings are Buy or Strong Buy.

    Bear case

    • PRQR has a -228.2% net profit margin.

    PRQR Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    9.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.11
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About PRQR

    Does PRQR pay dividends?

    ProQR Therapeutics BV (PRQR) does not currently pay a regular dividend.

    What is PRQR's market cap?

    ProQR Therapeutics BV (PRQR) has a market capitalization of $208.86M with a current stock price of $1.47.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In